Loading…
Lobbying Spend
—
Filings
18
Firms Hired
1
Active Period
2018–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: LOPER CONSULTING LLC
S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act S. 2210, Better Care Better Jobs Act; H.R. 5376, Build Back Better Act Prescription drug pricing issues. Issues of prescription drug pricing in Medicare and Medicaid. Rebate rule. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5376
Fair Accountability and Innovative Research Drug Pricing Act of 2019
2021 · fourth_quarter · Firm: LOPER CONSULTING LLC
S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act S. 2210, Better Care Better Jobs Act; H.R. 5376, Build Back Better Act Prescription drug pricing issues. Issues of prescription drug pricing in Medicare and Medicaid. Rebate rule. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: S.1391
S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act S. 2210, Better Care Better Jobs Act; H.R. 5376, Build Back Better Act Prescription drug pricing issues. Issues of prescription drug pricing in Medicare and Medicaid. Rebate rule. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: S. 2210
Protecting Medicare and American Farmers from Sequester Cuts Act
2021 · fourth_quarter · Firm: LOPER CONSULTING LLC
S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act S. 2210, Better Care Better Jobs Act; H.R. 5376, Build Back Better Act Prescription drug pricing issues. Issues of prescription drug pricing in Medicare and Medicaid. Rebate rule. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: S.610
Inflation Reduction Act of 2022
2021 · third_quarter · Firm: LOPER CONSULTING LLC
S. 2210, Better Care Better Jobs Act; H.R. 5376, Build Back Better Act Prescription drug pricing issues. Issues of prescription drug pricing in Medicare and Medicaid. Rebate rule. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5376
Fair Accountability and Innovative Research Drug Pricing Act of 2019
2021 · third_quarter · Firm: LOPER CONSULTING LLC
S. 2210, Better Care Better Jobs Act; H.R. 5376, Build Back Better Act Prescription drug pricing issues. Issues of prescription drug pricing in Medicare and Medicaid. Rebate rule. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: S.1391
S. 2210, Better Care Better Jobs Act; H.R. 5376, Build Back Better Act Prescription drug pricing issues. Issues of prescription drug pricing in Medicare and Medicaid. Rebate rule. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: S. 2210
Fair Accountability and Innovative Research Drug Pricing Act of 2019
2021 · second_quarter · Firm: LOPER CONSULTING LLC
Prescription drug pricing issues. Continued monitoring of the implementation of Families First Coronavirus Response Act (PL 116-127); Issues of prescription drug pricing in Medicare and Medicaid. Rebate rule. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: S.1391
Fair Accountability and Innovative Research Drug Pricing Act of 2019
2021 · first_quarter · Firm: LOPER CONSULTING LLC
Continued monitoring of implementation of Families First Coronavirus Response Act (PL 116-127); Issues of prescription drug pricing in Medicare and Medicaid. Rebate rule. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019. Prescription drug pricing issues.
Client expense: — · Firm income: $20,000
Matched citations: S.1391
More Efficient Tools to Realize Information for Consumers Act
2020 · fourth_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the MFN and drug rebate rules H.R. 3 - The Lower Drug Costs Now Act S. 1895 - Lower Health Care Costs Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2296
Elijah E. Cummings Lower Drug Costs Now Act
2020 · fourth_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the MFN and drug rebate rules H.R. 3 - The Lower Drug Costs Now Act S. 1895 - Lower Health Care Costs Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 3
Issues related to drug pricing; issues related to the MFN and drug rebate rules H.R. 3 - The Lower Drug Costs Now Act S. 1895 - Lower Health Care Costs Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: S. 1209
Fair Accountability and Innovative Research Drug Pricing Act of 2019
2020 · fourth_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the MFN and drug rebate rules H.R. 3 - The Lower Drug Costs Now Act S. 1895 - Lower Health Care Costs Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: S. 1391
Issues related to drug pricing; issues related to the MFN and drug rebate rules H.R. 3 - The Lower Drug Costs Now Act S. 1895 - Lower Health Care Costs Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: S. 1895
Issues related to drug pricing; issues related to the MFN and drug rebate rules H.R. 3 - The Lower Drug Costs Now Act S. 1895 - Lower Health Care Costs Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: S. 440
Orange Book Transparency Act of 2020
2020 · third_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1503
Further Extension of Continuing Appropriations Act, 2021
2020 · third_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1520
More Efficient Tools to Realize Information for Consumers Act
2020 · third_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2296
Elijah E. Cummings Lower Drug Costs Now Act
2020 · third_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 3
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 965
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: S. 1209
Fair Accountability and Innovative Research Drug Pricing Act of 2019
2020 · third_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: S. 1391
Affordable Prescriptions for Patients Act of 2019
2020 · third_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: S. 1416
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: S. 1895
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2020 · third_quarter · Firm: LOPER CONSULTING LLC
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs. H.R. 3 - The Lower Drug Costs Now Act H.R. 965/ S. 340, CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Client expense: — · Firm income: $20,000
Matched citations: S. 340
Source: Senate LDA